A Phase 4 interventional study of Alirocumab SAR236553 and Atorvastatin in Hypercholesterolemia and Acute Coronary Syndrome, sponsored by Sanofi. Completed at 39 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2019-09-09.
Sponsored by Sanofi · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing alirocumab in Hypercholesterolemia — 1 open to participants now, 2 under way, none of them phase 3. alirocumab · Hypercholesterolemia.
Among the 43 studies testing alirocumab in Hypercholesterolemia, this one is the 18th largest by enrollment, is one of 5 that started in 2016, is one of 5 in phase 4, and was the 36th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →1 of the 43 studies testing alirocumab in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:
University Medical Centre Ljubljana · Sites in Slovenia
Ages 18+
By country, each count listing its studies:
alirocumab: first FDA approval 2015 (PRALUENT), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 5 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 206 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 107 across the 43 interventional studies. Of the 40 that completed or were terminated, 30 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 43 have an industry lead sponsor. The 6 most frequent:
Sanofi is the lead sponsor of 1,559 studies on the registry; 90 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
38 studies in Hypercholesterolemia by Sanofi: none open now, none under way, none of them phase 3. Of 38 finished, 22 (58%) have results posted.
Among the 38 studies in Hypercholesterolemia by Sanofi, this one is the 16th largest by enrollment, is one of 4 that started in 2016, is the only one in phase 4, and was the 34th registered.
Sanofi’s Hypercholesterolemia studies by the year they started, since 2007.
2 of the studies testing alirocumab in Hypercholesterolemia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07477704Regeneron PharmaceuticalsA Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia | 2026-12-29 |
| NCT07581808University Medical Centre LjubljanaDual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention | 2027-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 43 studies testing alirocumab in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 38 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To compare the efficacy of alirocumab (Praluent®) with standard of care (SoC) on coronary atheroma progression (percent change in normalized total atheroma volume [TAV]) after 9 months of treatment in participants who had acute coronary syndrome (ACS) within 4 weeks prior to randomization, with hypercholesterolemia treated with statin.
Secondary Objectives:
The duration of study per participant was 9 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Considered by the Investigator or any sub-Investigator as inappropriate for this study for any reason, including:
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Statin therapy (atorvastatin or rosuvastatin) will be administered with or without non-statin lipid modifying therapies (LMTs). Non-statin LMTs will be adjusted by physicians to achieve the LDL-C target level \<100 milligrams per deciliter (mg/dL).
Drug: Atorvastatin · Drug: Rosuvastatin · Drug: Fenofibrate · Drug: Bezafibrate · Drug: Ezetimibe · Drug: Antiplatelets · Drug: Anticoagulants
Alirocumab will be given subcutaneously every 2 weeks on top of stable dose statin therapy (atorvastatin or rosuvastatin) with or without stable dose non-statin LMTs.
Drug: Alirocumab SAR236553 · Drug: Atorvastatin · Drug: Rosuvastatin · Drug: Fenofibrate · Drug: Bezafibrate · Drug: Ezetimibe · Drug: Antiplatelets · Drug: Anticoagulants
Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
Also known as: Praluent
Pharmaceutical form: tablet Route of administration: oral
Pharmaceutical form: tablet Route of administration: oral
Pharmaceutical form: tablet Route of administration: oral
Pharmaceutical form: tablet Route of administration: oral
Pharmaceutical form: tablet Route of administration: oral
Pharmaceutical form: tablet or capsule Route of administration: oral
Pharmaceutical form: tablet or capsule Route of administration: oral
Percent Change From Baseline in Normalized Total Atheroma Volume (TAV) at Week 36
Least-squares (LS) means and standard errors (SE) at Week 36 were obtained from analysis of covariance (ANCOVA) model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset \[Yes / No\]) as fixed categorical effects, and the baseline normalized TAV as continuous fixed covariate.
Time frame: Baseline, Week 36
Absolute Change From Baseline in Percent Atheroma Volume (PAV) at Week 36
LS mean and SE at Week 36 were obtained from ANCOVA model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset \[Yes / No\]) as fixed categorical effects, and the baseline PAV as continuous fixed covariate.
Time frame: Baseline, Week 36
Absolute Change From Baseline in Normalized Total Atheroma Volume at Week 36
LS mean and SE at Week 36 were obtained from ANCOVA model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset \[Yes / No\]) as fixed categorical effects, and the baseline normalized TAV as continuous fixed covariate.
Time frame: Baseline, Week 36
Absolute Change From Baseline in External Elastic Membrane (EEM) Volume at Week 36
Adjusted mean and SE at Week 36 were obtained from robust regression model with treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset \[Yes / No\]), as fixed categorical effects, and the baseline EEM volume value as continuous fixed covariate.
Time frame: Baseline, Week 36
Percent Change From Baseline in External Elastic Membrane Volume at Week 36
Adjusted mean and SE at Week 36 were obtained from robust regression model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset \[Yes / No\]) as fixed categorical effects, and the baseline EEM volume value as continuous fixed covariate.
Time frame: Baseline, Week 36
Absolute Change From Baseline in Lumen Volume at Week 36
Adjusted mean and SE at Week 36 were obtained from robust regression model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset \[Yes / No\]) as fixed categorical effects, and the baseline lumen volume value as continuous fixed covariate.
Time frame: Baseline, Week 36
Percent Change From Baseline in Lumen Volume at Week 36
Adjusted mean and SE at Week 36 were obtained from robust regression model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset \[Yes / No\]) as fixed categorical effect, and the baseline lumen volume value as continuous fixed covariate.
Time frame: Baseline, Week 36
Absolute Change From Baseline in Calculated Low-density Lipoprotein Cholesterol at Week 12 and Week 36
Adjusted LS mean and SE at Week 12 and Week 36 were obtained from mixed-effect model including all available post-baseline data from Week 4 to Week 36. Model included treatment arm (SoC arm, alirocumab arm), randomization strata (statin at ACS onset \[Yes / No\]), time point, treatment-by-time point and randomization strata-by-time point interaction as fixed categorical effects, and baseline calculated LDL-C value and baseline calculated LDL-C value-by-time point interaction as continuous fixed covariates.
Time frame: Baseline, Week 12, Week 36
Percent Change From Baseline in Calculated Low-density Lipoprotein Cholesterol at Week 12 and Week 36
Adjusted LS mean and SE at Week 12 and Week 36 were obtained from mixed-effect model including all available post-baseline data from Week 4 to Week 36. Model included treatment arm (SoC arm, alirocumab arm), randomization strata (statin at ACS onset \[Yes / No\]), time point, treatment-by-time point and randomization strata-by-time point interaction as fixed categorical effects, and baseline calculated LDL-C value and baseline calculated LDL-C value-by-time point interaction as continuous fixed covariates.
Time frame: Baseline, Week 12, Week 36
Absolute Change From Baseline in Apolipoprotein B (Apo B) at Week 36
Adjusted LS mean and SE at Week 36 were obtained from ANCOVA model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset \[Yes / No\]) as fixed categorical effects, and baseline Apo B value as continuous fixed covariate.
Time frame: Baseline, Week 36
Percent Change From Baseline in Apolipoprotein B at Week 36
Adjusted LS mean and SE at Week 36 were obtained from ANCOVA model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset \[Yes / No\]) as fixed categorical effects, and baseline Apo B value as continuous fixed covariate.
Time frame: Baseline, Week 36
Absolute Change From Baseline in Non-High-density Lipoprotein Cholesterol (Non-HDL-C) at Week 36
Adjusted LS mean and SE at Week 36 were obtained from mixed-effect model including all available post-baseline data from Week 4 to Week 36. Model included treatment arm (SoC arm, alirocumab arm), randomization strata (statin at ACS onset \[Yes / No\]), time point, treatment-by-time point and randomization strata-by-time point interaction as fixed categorical effects, and baseline calculated non-HDL-C value and baseline calculated non-HDL-C value-by-time point interaction as continuous fixed covariates.
Time frame: Baseline, Week 36
Percent Change From Baseline in Non-High-density Lipoprotein Cholesterol at Week 36
Adjusted LS mean and SE at Week 36 were obtained from mixed-effect model including all available post-baseline data from Week 4 to Week 36. Model included treatment arm (SoC arm, alirocumab arm), randomization strata (statin at ACS onset \[Yes / No\]), time point, treatment-by-time point and randomization strata-by-time point interaction as fixed categorical effects, and baseline calculated non-HDL-C value and baseline calculated non-HDL-C value-by-time point interaction as continuous fixed covariates.
Time frame: Baseline, Week 36
Absolute Change From Baseline in Total Cholesterol (TC) at Week 36
LS mean and SE at Week 36 were obtained from mixed-effect model including all available post-baseline data from Week 4 to Week 36. Model included treatment arm (SoC arm, alirocumab arm), randomization strata (statin at ACS onset \[Yes / No\]), time point, treatment-by-time point and randomization strata-by-time point interaction as fixed categorical effects, and baseline calculated TC value and baseline calculated TC value-by-time point interaction as continuous fixed covariates.
Time frame: Baseline, Week 36
Percent Change From Baseline in Total Cholesterol at Week 36
Adjusted LS mean and SE at Week 36 were obtained from mixed-effect model including all available post-baseline data from Week 4 to Week 36. Model included treatment arm (SoC arm, alirocumab arm), randomization strata (statin at ACS onset \[Yes / No\]), time point, treatment-by-time point and randomization strata-by-time point interaction as fixed categorical effects, and baseline TC value and baseline TC value-by-time point interaction as continuous fixed covariates.
Time frame: Baseline, Week 36
Absolute Change From Baseline in Lipoprotein (a) (Lp[a]) at Week 36
Adjusted mean and SE at Week 36 were obtained from robust regression model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset \[Yes / No\]) as fixed categorical effect, and baseline Lp(a) value as continuous fixed covariate.
Time frame: Baseline, Week 36
Percent Change From Baseline in Lipoprotein (a) at Week 36
Adjusted mean and SE at Week 36 were obtained from robust regression model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset \[Yes / No\]) as fixed categorical effect, and baseline Lp(a) value as continuous fixed covariate.
Time frame: Baseline, Week 36
Absolute Change From Baseline in High-density Lipoprotein Cholesterol at Week 36
Adjusted LS mean and SE at Week 36 were obtained from mixed-effect model including all available post-baseline data from Week 4 to Week 36. Model included treatment arm (SoC arm, alirocumab arm), randomization strata (statin at ACS onset \[Yes / No\]), time point, treatment-by-time point and randomization strata-by-time point interaction as fixed categorical effects, and baseline HDL-C value and baseline HDL-C value-by-time point interaction as continuous fixed covariates.
Time frame: Baseline, Week 36
Percent Change From Baseline in High-density Lipoprotein Cholesterol at Week 36
Adjusted LS mean and SE at Week 36 were obtained from mixed-effect model including all available post-baseline data from Week 4 to Week 36. Model included treatment arm (SoC arm, alirocumab arm), randomization strata (statin at ACS onset \[Yes / No\]), time point, treatment-by-time point and randomization strata-by-time point interaction as fixed categorical effects, and baseline HDL-C value and baseline HDL-C value-by-time point interaction as continuous fixed covariates.
Time frame: Baseline, Week 36
Absolute Change From Baseline in Fasting Triglycerides (TGs) at Week 36
Adjusted mean and SE were obtained from multiple imputation approach followed by robust regression model including fixed categorical effect of treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset \[Yes / No\]) and the continuous fixed covariate of baseline fasting TGs value.
Time frame: Baseline, Week 36
Percent Change From Baseline in Fasting Triglycerides at Week 36
Adjusted mean and SE were obtained by multiple imputation approach followed by robust regression model included fixed categorical effect of treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset \[Yes / No\]) and the continuous fixed covariate of baseline fasting TGs value.
Time frame: Baseline, Week 36
Absolute Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 36
Adjusted LS mean and SE at Week 36 were obtained from ANCOVA model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset \[Yes / No\]) as fixed categorical effects, and baseline Apo A-1 value as continuous fixed covariate.
Time frame: Baseline, Week 36
Percent Change From Baseline in Apolipoprotein A-1 at Week 36
Adjusted LS mean and SE at Week 36 were obtained from ANCOVA model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset \[Yes / No\]) as fixed categorical effects, and baseline Apo A-1 value as continuous fixed covariate.
Time frame: Baseline, Week 36
Number of Participants With Cardiovascular (CV) Adverse Events
The suspected or confirmed CV events that occurred from randomization until end of the study visit were collected and reported. The various CV events included CV death, myocardial infarction, ischemic stroke, unstable angina requiring hospitalization , congestive heart failure requiring hospitalization, congestive heart failure requiring hospitalization, ischemia-driven coronary revascularization procedure.
Time frame: Up to 36 weeks
The study was conducted at 39 active centers in Japan. Overall 214 participants were screened between 15 November 2016 and 02 November 2017, of whom 8 were screen failure and 206 were randomized to either alirocumab arm or standard of care (SoC) arm.
| Milestone | Standard of Care | Alirocumab |
|---|---|---|
| Started | 102 | 104 |
| Treated | 102 | 103 |
| Completed | 94 | 94 |
| Not completed | 8 | 10 |
| Withdrew: Adverse event | 2 | 5 |
| Withdrew: Poor compliance to protocol | 4 | 4 |
| Withdrew: Withdrawal by subject | 2 | 0 |
| Withdrew: Randomized but not treated | 0 | 1 |
Least-squares (LS) means and standard errors (SE) at Week 36 were obtained from analysis of covariance (ANCOVA) model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset \[Yes / No\]) as fixed categorical effects, and the baseline normalized TAV as continuous fixed covariate.
| percent change | Standard of Care | Alirocumab |
|---|---|---|
| Percent Change From Baseline in Normalized Total Atheroma Volume (TAV) at Week 36 | -3.14 ± 0.97 | -4.79 ± 0.95 |
LS mean and SE at Week 36 were obtained from ANCOVA model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset \[Yes / No\]) as fixed categorical effects, and the baseline PAV as continuous fixed covariate.
| percent atheroma volume | Standard of Care | Alirocumab |
|---|---|---|
| Absolute Change From Baseline in Percent Atheroma Volume (PAV) at Week 36 | -1.28 ± 0.39 | -1.42 ± 0.38 |
LS mean and SE at Week 36 were obtained from ANCOVA model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset \[Yes / No\]) as fixed categorical effects, and the baseline normalized TAV as continuous fixed covariate.
| cubic millimeter (mm^3) | Standard of Care | Alirocumab |
|---|---|---|
| Absolute Change From Baseline in Normalized Total Atheroma Volume at Week 36 | -4.73 ± 1.02 | -5.77 ± 1.00 |
Adjusted mean and SE at Week 36 were obtained from robust regression model with treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset \[Yes / No\]), as fixed categorical effects, and the baseline EEM volume value as continuous fixed covariate.
| mm^3 | Standard of Care | Alirocumab |
|---|---|---|
| Absolute Change From Baseline in External Elastic Membrane (EEM) Volume at Week 36 | -8.23 ± 1.85 | -10.01 ± 1.81 |
Adjusted mean and SE at Week 36 were obtained from robust regression model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset \[Yes / No\]) as fixed categorical effects, and the baseline EEM volume value as continuous fixed covariate.
| percent change | Standard of Care | Alirocumab |
|---|---|---|
| Percent Change From Baseline in External Elastic Membrane Volume at Week 36 | -0.86 ± 0.93 | -3.18 ± 0.91 |
Adjusted mean and SE at Week 36 were obtained from robust regression model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset \[Yes / No\]) as fixed categorical effects, and the baseline lumen volume value as continuous fixed covariate.
| mm^3 | Standard of Care | Alirocumab |
|---|---|---|
| Absolute Change From Baseline in Lumen Volume at Week 36 | -1.25 ± 1.38 | -0.93 ± 1.35 |
Adjusted mean and SE at Week 36 were obtained from robust regression model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset \[Yes / No\]) as fixed categorical effect, and the baseline lumen volume value as continuous fixed covariate.
| percent change | Standard of Care | Alirocumab |
|---|---|---|
| Percent Change From Baseline in Lumen Volume at Week 36 | 1.20 ± 1.26 | -0.86 ± 1.23 |
Adjusted LS mean and SE at Week 12 and Week 36 were obtained from mixed-effect model including all available post-baseline data from Week 4 to Week 36. Model included treatment arm (SoC arm, alirocumab arm), randomization strata (statin at ACS onset \[Yes / No\]), time point, treatment-by-time point and randomization strata-by-time point interaction as fixed categorical effects, and baseline calculated LDL-C value and baseline calculated LDL-C value-by-time point interaction as continuous fixed covariates.
| mg/dL | Standard of Care | Alirocumab |
|---|---|---|
| Week 12 | -9.6 ± 1.7 | -62.4 ± 1.6 |
| Week 36 | -15.5 ± 1.8 | -63.2 ± 1.8 |
Adjusted LS mean and SE at Week 12 and Week 36 were obtained from mixed-effect model including all available post-baseline data from Week 4 to Week 36. Model included treatment arm (SoC arm, alirocumab arm), randomization strata (statin at ACS onset \[Yes / No\]), time point, treatment-by-time point and randomization strata-by-time point interaction as fixed categorical effects, and baseline calculated LDL-C value and baseline calculated LDL-C value-by-time point interaction as continuous fixed covariates.
| percent change | Standard of Care | Alirocumab |
|---|---|---|
| Week 12 | -7.57 ± 1.91 | -64.53 ± 1.83 |
| Week 36 | -13.40 ± 1.99 | -63.94 ± 1.91 |
Adjusted LS mean and SE at Week 36 were obtained from ANCOVA model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset \[Yes / No\]) as fixed categorical effects, and baseline Apo B value as continuous fixed covariate.
| mg/dL | Standard of Care | Alirocumab |
|---|---|---|
| Absolute Change From Baseline in Apolipoprotein B (Apo B) at Week 36 | -16.8 ± 1.4 | -51.0 ± 1.3 |
Adjusted LS mean and SE at Week 36 were obtained from ANCOVA model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset \[Yes / No\]) as fixed categorical effects, and baseline Apo B value as continuous fixed covariate.
| percent change | Standard of Care | Alirocumab |
|---|---|---|
| Percent Change From Baseline in Apolipoprotein B at Week 36 | -16.61 ± 1.56 | -55.13 ± 1.53 |
Adjusted LS mean and SE at Week 36 were obtained from mixed-effect model including all available post-baseline data from Week 4 to Week 36. Model included treatment arm (SoC arm, alirocumab arm), randomization strata (statin at ACS onset \[Yes / No\]), time point, treatment-by-time point and randomization strata-by-time point interaction as fixed categorical effects, and baseline calculated non-HDL-C value and baseline calculated non-HDL-C value-by-time point interaction as continuous fixed covariates.
| mg/dL | Standard of Care | Alirocumab |
|---|---|---|
| Absolute Change From Baseline in Non-High-density Lipoprotein Cholesterol (Non-HDL-C) at Week 36 | -20.3 ± 2.0 | -69.2 ± 2.0 |
Adjusted LS mean and SE at Week 36 were obtained from mixed-effect model including all available post-baseline data from Week 4 to Week 36. Model included treatment arm (SoC arm, alirocumab arm), randomization strata (statin at ACS onset \[Yes / No\]), time point, treatment-by-time point and randomization strata-by-time point interaction as fixed categorical effects, and baseline calculated non-HDL-C value and baseline calculated non-HDL-C value-by-time point interaction as continuous fixed covariates.
| percent change | Standard of Care | Alirocumab |
|---|---|---|
| Percent Change From Baseline in Non-High-density Lipoprotein Cholesterol at Week 36 | -14.06 ± 1.71 | -54.50 ± 1.67 |
LS mean and SE at Week 36 were obtained from mixed-effect model including all available post-baseline data from Week 4 to Week 36. Model included treatment arm (SoC arm, alirocumab arm), randomization strata (statin at ACS onset \[Yes / No\]), time point, treatment-by-time point and randomization strata-by-time point interaction as fixed categorical effects, and baseline calculated TC value and baseline calculated TC value-by-time point interaction as continuous fixed covariates.
| mg/dL | Standard of Care | Alirocumab |
|---|---|---|
| Absolute Change From Baseline in Total Cholesterol (TC) at Week 36 | -15.2 ± 2.3 | -61.7 ± 2.2 |
Adjusted LS mean and SE at Week 36 were obtained from mixed-effect model including all available post-baseline data from Week 4 to Week 36. Model included treatment arm (SoC arm, alirocumab arm), randomization strata (statin at ACS onset \[Yes / No\]), time point, treatment-by-time point and randomization strata-by-time point interaction as fixed categorical effects, and baseline TC value and baseline TC value-by-time point interaction as continuous fixed covariates.
| percent change | Standard of Care | Alirocumab |
|---|---|---|
| Percent Change From Baseline in Total Cholesterol at Week 36 | -7.59 ± 1.35 | -35.43 ± 1.32 |
Adjusted mean and SE at Week 36 were obtained from robust regression model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset \[Yes / No\]) as fixed categorical effect, and baseline Lp(a) value as continuous fixed covariate.
| mg/dL | Standard of Care | Alirocumab |
|---|---|---|
| Absolute Change From Baseline in Lipoprotein (a) (Lp[a]) at Week 36 | -10.3 ± 0.5 | -15.5 ± 0.5 |
Adjusted mean and SE at Week 36 were obtained from robust regression model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset \[Yes / No\]) as fixed categorical effect, and baseline Lp(a) value as continuous fixed covariate.
| percent change | Standard of Care | Alirocumab |
|---|---|---|
| Percent Change From Baseline in Lipoprotein (a) at Week 36 | -17.23 ± 2.60 | -55.76 ± 2.54 |
Adjusted LS mean and SE at Week 36 were obtained from mixed-effect model including all available post-baseline data from Week 4 to Week 36. Model included treatment arm (SoC arm, alirocumab arm), randomization strata (statin at ACS onset \[Yes / No\]), time point, treatment-by-time point and randomization strata-by-time point interaction as fixed categorical effects, and baseline HDL-C value and baseline HDL-C value-by-time point interaction as continuous fixed covariates.
| mg/dL | Standard of Care | Alirocumab |
|---|---|---|
| Absolute Change From Baseline in High-density Lipoprotein Cholesterol at Week 36 | 4.7 ± 0.9 | 8.1 ± 0.9 |
Adjusted LS mean and SE at Week 36 were obtained from mixed-effect model including all available post-baseline data from Week 4 to Week 36. Model included treatment arm (SoC arm, alirocumab arm), randomization strata (statin at ACS onset \[Yes / No\]), time point, treatment-by-time point and randomization strata-by-time point interaction as fixed categorical effects, and baseline HDL-C value and baseline HDL-C value-by-time point interaction as continuous fixed covariates.
| percent change | Standard of Care | Alirocumab |
|---|---|---|
| Percent Change From Baseline in High-density Lipoprotein Cholesterol at Week 36 | 12.19 ± 2.30 | 21.04 ± 2.25 |
Adjusted mean and SE were obtained from multiple imputation approach followed by robust regression model including fixed categorical effect of treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset \[Yes / No\]) and the continuous fixed covariate of baseline fasting TGs value.
| mg/dL | Standard of Care | Alirocumab |
|---|---|---|
| Absolute Change From Baseline in Fasting Triglycerides (TGs) at Week 36 | -26.2 ± 4.7 | -35.3 ± 4.5 |
Adjusted mean and SE were obtained by multiple imputation approach followed by robust regression model included fixed categorical effect of treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset \[Yes / No\]) and the continuous fixed covariate of baseline fasting TGs value.
| percent change | Standard of Care | Alirocumab |
|---|---|---|
| Percent Change From Baseline in Fasting Triglycerides at Week 36 | -8.85 ± 3.62 | -18.37 ± 3.51 |
Adjusted LS mean and SE at Week 36 were obtained from ANCOVA model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset \[Yes / No\]) as fixed categorical effects, and baseline Apo A-1 value as continuous fixed covariate.
| mg/dL | Standard of Care | Alirocumab |
|---|---|---|
| Absolute Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 36 | 3.8 ± 1.9 | 12.0 ± 1.9 |
Adjusted LS mean and SE at Week 36 were obtained from ANCOVA model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset \[Yes / No\]) as fixed categorical effects, and baseline Apo A-1 value as continuous fixed covariate.
| percent change | Standard of Care | Alirocumab |
|---|---|---|
| Percent Change From Baseline in Apolipoprotein A-1 at Week 36 | 4.61 ± 1.62 | 11.75 ± 1.58 |
The suspected or confirmed CV events that occurred from randomization until end of the study visit were collected and reported. The various CV events included CV death, myocardial infarction, ischemic stroke, unstable angina requiring hospitalization , congestive heart failure requiring hospitalization, congestive heart failure requiring hospitalization, ischemia-driven coronary revascularization procedure.
| Participants | Standard of Care | Alirocumab |
|---|---|---|
| Cardiovascular death | 0 | 0 |
| Myocardial infarction | 3 | 2 |
| Ischemic stroke | 0 | 2 |
| Unstable angina requiring hospitalization | 0 | 0 |
| Congestive heart failure requiring hospitalization | 0 | 0 |
| Ischemia led coronary revascularization procedure | 2 | 4 |
Collected over All Adverse Events (AEs) were collected from signature of the informed consent form up to 21 days after last dose of study drug, or end of study, whichever comes first (up to 39 weeks) regardless of seriousness or relationship to investigational product. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Standard of Care | 1/102 (1%) | 17/102 (16.7%) | 15/102 (14.7%) |
| Alirocumab | 0/103 (0%) | 19/103 (18.4%) | 33/103 (32%) |
| Event | Standard of Care | Alirocumab |
|---|---|---|
| Myocardial ischaemiaCardiac disorders | 3/102 | 1/103 |
| Coronary artery stenosisCardiac disorders | 0/102 | 3/103 |
| PneumoniaInfections and infestations | 2/102 | 1/103 |
| Acute myocardial infarctionCardiac disorders | 2/102 | 2/103 |
| Myocardial infarctionCardiac disorders | 2/102 | 1/103 |
| Cerebral infarctionNervous system disorders | 0/102 | 2/103 |
| SepsisInfections and infestations | 1/102 | 0/103 |
| Rectal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/102 | 0/103 |
| Transient ischaemic attackNervous system disorders | 1/102 | 1/103 |
| Acute coronary syndromeCardiac disorders | 1/102 | 0/103 |
| Event | Standard of Care | Alirocumab |
|---|---|---|
| NasopharyngitisInfections and infestations | 15/102 | 27/103 |
| Injection site reactionGeneral disorders | 0/102 | 7/103 |
| Back painMusculoskeletal and connective tissue disorders | 0/102 | 6/103 |
Randomized population included all participants who were allocated to a randomized treatment and recorded in the registration center database, regardless of whether a study drug was used or not.
| Age, Continuous(years) | Standard of Care | Alirocumab | Total |
|---|---|---|---|
| Mean | 60.0 ± 11.9 | 61.7 ± 10.9 | 60.9 ± 11.4 |
| Sex: Female, Male(Participants) | Standard of Care | Alirocumab | Total |
|---|---|---|---|
| Female | 19 | 21 | 40 |
| Male | 83 | 83 | 166 |
| Race (NIH/OMB)(Participants) | Standard of Care | Alirocumab | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 102 | 104 | 206 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Calculated LDL-C in mg/dL(mg/dL) | Standard of Care | Alirocumab | Total |
|---|---|---|---|
| Mean | 95.2 ± 22.6 | 98.5 ± 22.9 | 96.9 ± 22.8 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Not available for request.
Ran from Nov 2016 to primary completion in Jul 2018, 20 months.
Results were first posted in Sep 2019, 1 year 1 month after primary completion.
Of 40 phase 4 interventional studies under Hypercholesterolemia, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 20 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alirocumab